Mayinglong Pharmaceutical Group Co., Ltd. (SHA:600993)
China · Delayed Price · Currency is CNY 25.90
-0.06 (-0.23%)
Apr 28, 2026, 3:00 PM CST
SHA:600993 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 3,910 | 3,867 | 3,680 | 3,098 | 3,497 | 3,363 |
Other Revenue | - | - | 48.5 | 38.3 | 35.12 | 22.53 |
| 3,910 | 3,867 | 3,728 | 3,137 | 3,532 | 3,385 | |
Revenue Growth (YoY) | 4.48% | 3.72% | 18.85% | -11.20% | 4.35% | 21.26% |
Cost of Revenue | 2,004 | 1,965 | 1,997 | 1,829 | 2,038 | 2,019 |
Gross Profit | 1,906 | 1,902 | 1,731 | 1,307 | 1,494 | 1,366 |
Selling, General & Admin | 1,144 | 1,147 | 1,051 | 825.21 | 886.06 | 818.05 |
Research & Development | 76.34 | 78.11 | 66.69 | 69.01 | 77.89 | 66.73 |
Other Operating Expenses | 9.99 | 7.02 | 26.29 | 24.39 | 26.16 | 25.06 |
Operating Expenses | 1,231 | 1,232 | 1,153 | 922.54 | 1,000 | 912.9 |
Operating Income | 675.71 | 669.73 | 578.43 | 384.73 | 494.16 | 453.38 |
Interest Expense | - | - | -7.38 | -16.85 | -11.69 | -10.21 |
Interest & Investment Income | 33.99 | 29.62 | 78.88 | 151.5 | 98.92 | 78.85 |
Currency Exchange Gain (Loss) | - | - | -0.06 | 0.05 | 0.04 | -0.21 |
Other Non Operating Income (Expenses) | 18.93 | 18.88 | 0.99 | -3.78 | -6.22 | -4.92 |
EBT Excluding Unusual Items | 728.63 | 718.23 | 650.87 | 515.65 | 575.22 | 516.89 |
Gain (Loss) on Sale of Investments | -5.46 | -5.77 | -6.57 | -0.35 | -38.06 | 17.63 |
Gain (Loss) on Sale of Assets | -0.08 | -0.09 | -0.14 | 1.12 | -0.01 | -0.5 |
Asset Writedown | -5.27 | -3.37 | -5.25 | - | -0.34 | -0.44 |
Other Unusual Items | - | - | 18.64 | 8.28 | 22.33 | 14.58 |
Pretax Income | 717.82 | 709 | 657.55 | 524.7 | 559.14 | 548.16 |
Income Tax Expense | 102.84 | 103.29 | 109.26 | 72.86 | 79.78 | 74.11 |
Earnings From Continuing Operations | 614.98 | 605.71 | 548.3 | 451.84 | 479.35 | 474.05 |
Minority Interest in Earnings | -24.48 | -24.22 | -20.2 | -8.59 | -0.78 | -9.46 |
Net Income | 590.51 | 581.49 | 528.09 | 443.25 | 478.57 | 464.59 |
Net Income to Common | 590.51 | 581.49 | 528.09 | 443.25 | 478.57 | 464.59 |
Net Income Growth | 10.58% | 10.11% | 19.14% | -7.38% | 3.01% | 10.87% |
Shares Outstanding (Basic) | 431 | 431 | 429 | 430 | 431 | 430 |
Shares Outstanding (Diluted) | 431 | 431 | 429 | 430 | 431 | 430 |
Shares Change (YoY) | 0.17% | 0.32% | -0.23% | -0.19% | 0.22% | -0.43% |
EPS (Basic) | 1.37 | 1.35 | 1.23 | 1.03 | 1.11 | 1.08 |
EPS (Diluted) | 1.37 | 1.35 | 1.23 | 1.03 | 1.11 | 1.08 |
EPS Growth | 10.40% | 9.76% | 19.42% | -7.21% | 2.78% | 11.34% |
Free Cash Flow | 596.17 | 481.07 | 293.76 | 355.7 | 266.84 | 532.07 |
Free Cash Flow Per Share | 1.38 | 1.12 | 0.68 | 0.83 | 0.62 | 1.24 |
Dividend Per Share | - | - | 0.620 | 0.400 | 0.350 | 0.350 |
Dividend Growth | - | - | 55.00% | 14.29% | - | 16.67% |
Gross Margin | 48.76% | 49.19% | 46.43% | 41.68% | 42.30% | 40.36% |
Operating Margin | 17.28% | 17.32% | 15.52% | 12.26% | 13.99% | 13.39% |
Profit Margin | 15.10% | 15.04% | 14.17% | 14.13% | 13.55% | 13.73% |
Free Cash Flow Margin | 15.25% | 12.44% | 7.88% | 11.34% | 7.55% | 15.72% |
EBITDA | 748.96 | 737.05 | 622.05 | 434.2 | 541.14 | 495.12 |
EBITDA Margin | 19.16% | 19.06% | 16.69% | 13.84% | 15.32% | 14.63% |
D&A For EBITDA | 73.25 | 67.32 | 43.62 | 49.48 | 46.98 | 41.74 |
EBIT | 675.71 | 669.73 | 578.43 | 384.73 | 494.16 | 453.38 |
EBIT Margin | 17.28% | 17.32% | 15.52% | 12.26% | 13.99% | 13.39% |
Effective Tax Rate | 14.33% | 14.57% | 16.61% | 13.89% | 14.27% | 13.52% |
Revenue as Reported | - | - | 3,728 | 3,137 | 3,532 | 3,385 |
Advertising Expenses | - | - | 161.64 | 72.56 | 81.25 | 59.99 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.